VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISHL HL Update 2021 | 1st-line therapies in Hodgkin lymphoma

Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, discusses innovative 1st-line therapies currently being evaluated in patients with Hodgkin lymphoma, the perspective of the German Hodgkin Study Group, including the ongoing HD21 trial (NCT02661503), as well as elderly patients with Hodgkin lymphoma, who represent an area of unmet need. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter